1. Home
  2. SONN

as 05-09-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Founded: N/A Country:
United States
United States
Employees: N/A City: PRINCETON
Market Cap: 4.6M IPO Year: N/A
Target Price: $38.00 AVG Volume (30 days): 31.5K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -9.05 EPS Growth: N/A
52 Week Low/High: $1.10 - $16.00 Next Earning Date: 05-16-2025
Revenue: $1,000,000 Revenue Growth: 674.14%
Revenue Growth (this year): 5376.22% Revenue Growth (next year): N/A

SONN Daily Stock ML Predictions

Share on Social Networks: